Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Aug 12;9(8):870.
doi: 10.3390/nu9080870.

Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study

Ludovico Abenavoli  1 , Marta Greco  2 , Natasa Milic  3 , Francesca Accattato  4 , Daniela Foti  5 , Elio Gulletta  6 , Francesco Luzza  7
Affiliations
Randomized Controlled Trial

Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study

Ludovico Abenavoli et al. Nutrients. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, characterized by liver fatty acid accumulation and fibrosis, not due to excessive alcohol consumption. Notably, nutritional habits have been reported to be implicated in the onset and severity of the hepatic damage, while the Mediterranean diet has shown beneficial effects on NAFLD. Free radicals and oxidative stress were suggested to be involved in the pathogenesis and progression of NAFLD, and several data highlighted the efficacy of antioxidant supplementation in its treatment. The aim of this study was to compare the effects of the Mediterranean diet, with or without an antioxidant complex supplement, in overweight patients suffering from NAFLD. In this prospective study, fifty Caucasian overweight patients were randomized into three groups (Groups A-C). A personalized moderately hypocaloric Mediterranean diet was prescribed to all patients included in the A and B groups. In addition to the diet, Group B was administered antioxidant supplementation daily and for the period of six months. Group C did not have any type of treatment. The study proved that the Mediterranean diet alone or in association with the antioxidant complex improved anthropometric parameters, lipid profile and reduced hepatic fat accumulation and liver stiffness. However, Group B patients, in which the diet was associated with antioxidant intake, showed not only a significant improvement in insulin sensitivity, but also a more consistent reduction of anthropometric parameters when compared with Group A patients. Taken together, these results support the benefit of antioxidant supplementation in overweight patients with NAFLD.

Keywords: Mediterranean diet; antioxidant; insulin resistance; non-alcoholic fatty liver disease; weight.

PubMed Disclaimer

Conflict of interest statement

The authors confirm that they have no conflicts of interest whatsoever, not even with the company that produces Bilirel (Pharmaluce, Republic of San Marino). This is in line with our conflicts of interest statement.

Figures

Figure 1
Figure 1
Comparison of fasting glucose (A); insulin (B) and HOMA-IR (C) at baseline (T0) and after six months (T6), among the three groups (Group A = diet; Group B = diet/BIL complex; Group C = control, without diet and antioxidant supplementation).
See this image and copyright information in PMC

References

    1. Masarone M., Federico A., Abenavoli L., Loguercio C., Persico M. Non alcoholic fatty liver: Epidemiology and natural history. Rev. Recent Clin. Trials. 2014;9:126–133. doi: 10.2174/1574887109666141216111143. - DOI - PubMed
    1. Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37:81–84. doi: 10.1111/liv.13299. - DOI - PubMed
    1. Lonardo A., Ballestri S., Guaraldi G., Nascimbeni F., Romagnoli D., Zona S., Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease—Evidence from three different disease models: NAFLD, HCV and HIV. World J. Gastroenterol. 2016;22:9674–9693. doi: 10.3748/wjg.v22.i44.9674. - DOI - PMC - PubMed
    1. Abenavoli L., Milic N., Di Renzo L., Preveden T., Medić-Stojanoska M., De Lorenzo A. Metabolic aspects of adult patients with nonalcoholic fatty liver disease. World J. Gastroenterol. 2016;22:7006–7016. doi: 10.3748/wjg.v22.i31.7006. - DOI - PMC - PubMed
    1. Kobyliak N., Abenavoli L. The role of liver biopsy to assess non-alcoholic fatty liver disease. Rev. Recent Clin. Trials. 2014;9:159–169. doi: 10.2174/1574887109666141216102231. - DOI - PubMed

Publication types